FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
More than 3,500 participants will join the nationwide AI-focused hackathon hosted as Indian Institute of Science
Report highlights growing confidence in digitalisation and AI, even as healthcare leaders remain concerned about workforce gaps, cybersecurity, and data readiness
Leadership transition strengthens Redcliffe Labs’ focus on scaling technology-led diagnostics, operational excellence, and preventive healthcare access
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
